These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Moss RB Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714 [TBL] [Abstract][Full Text] [Related]
17. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383 [TBL] [Abstract][Full Text] [Related]
18. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232 [TBL] [Abstract][Full Text] [Related]
19. Role of Aspergillus and Candida species in allergic bronchopulmonary mycoses. A comparative study. Sandhu RS; Mehta SK; Khan ZU; Singh MM Scand J Respir Dis; 1979 Oct; 60(5):235-42. PubMed ID: 118528 [TBL] [Abstract][Full Text] [Related]